GlassScriptPhysician profile
Steven H Schechter
NPI 1902897390
$149,042.37
in general payments reported to CMS, 2019-2025
78 companies · $4,214 in 2025
The $4,214 reported for 2025 was more than what 83% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $12K · 2021: $19K · 2022: $7,860 · 2023: $24K · 2024: $4,119 · 2025: $4,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Consulting Fee: $7,640 · Travel and Lodging: $1,055 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,663.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,590.00 |
| Consulting Fee | $7,640.00 |
| Travel and Lodging | $1,054.54 |
| Education | $226.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $39,630.24 | 2019-2021 | |
| Genzyme Corporation | $25,048.40 | 2019-2025 | |
| Lilly USA, LLC | $16,063.32 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Celgene Corporation | $9,939.24 | 2019-2025 | Zeposia |
| Corium, LLC | $9,368.06 | 2022-2023 | Azstarys, Adlarity |
| Abbvie INC. | $9,044.31 | 2019-2025 | Duopa, Ubrelvy, Qulipta |
| Genentech USA, INC. | $7,121.60 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Novartis Pharmaceuticals Corporation | $6,222.92 | 2019-2025 | Mayzent |
| Allergan, INC. | $4,623.07 | 2019-2021 | |
| Ucb, INC. | $2,590.90 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Emd Serono, INC. | $1,836.21 | 2019-2025 | Mavenclad |
| Amneal Pharmaceuticals LLC | $1,654.46 | 2019-2025 | Crexont |
| Biogen, INC. | $1,555.95 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Neurocrine Biosciences, INC. | $1,396.44 | 2020-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $1,144.08 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
Show all 77 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Schechter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.